Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 518-523

  Han, Sun Young ^a,d   Lee, Chong Ock ^a   Ahn, Sung Hoon ^a   Lee, Mi Ok ^b,c   Kang, So Young ^b,c   Cha, Hyuk Jin ^b,c   Cho, Sung Yun ^a   Ha, Jae Du ^a   Ryu, Jae Wook ^a   Jung, Heejung ^a   Kim, Hyoung Rae ^a   Koh, Jong Sung ^a   Lee, Jongkook ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b CHA University   (South Korea)

^c CHA University   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

Aminopyridine; c Met; Cancer; Flt3; Kinase inhibitor; Ron

Indexed keywords

CD135 ANTIGEN; CYTOCHROME P450; KRC 108; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE A; RON KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; KRC-108; PROTEIN TYROSINE KINASE; RON PROTEIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; IC 50; LUNG TUMOR; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; TUMOR VOLUME;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FMS-LIKE TYROSINE KINASE 3; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861576695     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9584-2     Document Type: Article

References (26)

1. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39. doi:10.1038/nrc2559
2. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10:130-137. doi:10.1038/nrc2787
3. Jänne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8:709-723. doi:10.1038/nrd2871
4. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792
5. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280. doi:10.1038/ncponc0509
6. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745. doi:10.1038/nrd2380
7. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelly S (2006) Nat Rev Drug Discov 5:835-844. doi:10.1038/nrd2130
8. Cho SY, Han S-Y, Ha JD, Ryu JW, Lee CO, Jung H, Kang NS, Kim HR, Koh JS, Lee J (2010) Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorg Med Chem Lett 20:4223-4227. doi:10.1016/j.bmcl.2010.05.031
9. Asses Y, Leroux V, Tairi-Kellou S, Dono R, Maina F, Maigret B (2009) Chem Biol Drug Des 74:560-570. doi:10.1111/j.1747-0285.2009.00895.x, and references cited
10. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung P-P, Nambu MD, Loss G, Bender SL, Mroczkowski B, Christensen JG (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408-4417. doi:10.1158/0008-5472. CAN-06-4443
11. Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, Murray BW (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochem 48:5339-5349. doi:10.1021/bi900438w
12. Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A, Basilico C, Michieli P, Comoglio PM (2000) Different point mutations in the met oncogene elicit distinct biological properties. FASEB J 14:399-406
13. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 18:2343-2350
14. Chen Y-Q, Zhou Y-Q, Angeloni D, Kurtz AL, Qiang X-Z, Wang M-H (2000) Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261:229-238. doi:10.1006/excr.2000.5012
15. Wagh PK, Peace BE, Waltz SE (2008) Met-related receptor tyrosine kinase ron in tumor growth and metastasis. Adv Cancer Res 100:1-33
16. Lu Y, Yao H-P, Wang M-H (2007) Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257:157-164. doi:10.1016/j.canlet.2007.08.007
17. Knapper S (2007) FLT3 inhibition in acute myeloid leukemia. Br J Haematol 138:687-699. doi:10.1111/j.1365-2141.2007.06700.x
18. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X (2009) TrkA overexpression enhances growth andmetastasis of breast cancer cells. Oncogene 28:1960-1970. doi:10.1038/onc.2009.61
19. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53:35-69. doi:10.1016/j.critrevonc.2004.09.004
20. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516. doi:10.1038/nrd2530
21. Christensen JG, Burrows J, Salgia R (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1-26. doi:10.1016/j.canlet.2004.09.044
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. doi:10.1126/science.1141478
23. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH (2003) FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction associated kinases. Clin Cancer Res 9:4483-4493
24. Xerri L, Parc P, Hassoun J, Birnbaum D (1996) Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol 178:128-132. doi:10.1002/(SICI)1096-9896(199602) 178:2<128::AID-PATH444>3.0.CO;2-H
25. Kerns EH, Di L (2007) Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. In: Cytochrome P450 inhibition. Academic Press, Oxford, pp 197-208 and references cited
26. de Groot MJ, Wakenhut F, Whitlock G, Hyland R (2009) Understanding CYP2D6 interactions. Drug Discov Today 14:964-972. doi:10.1016/j.drudis.2009.07.005